Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer
      QxMD      Google Scholar   
Citation:
JAMA vol 325 (13) 1277-85
Year:
2021
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
Alliance-data-source,-internal-user
Status:
Presented/Published
Citation Status:
ppub
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
10
Parents:
3228  
Children:
None
Program:
OGC
Primary Committee:
GI
Sec. Committees:
   
Pharmas:
Pfizer  
Grants:
U10CA180821, U10CA180882, U10CA180794, UG1CA233163, UG1CA233253, UG1CA233290, UG1CA233320, UG1CA233337, UG1CA233339, UG1CA189954, U10CA180863 (CCTG); UG1CA233196, U10CA180820 (ECOG-ACRIN); U10CA180868 (NRG); U10CA180888 (SWOG);  
Corr. Author:
 
Authors:
                                             
Networks:
CA136, HEARTLAND, LAPS-CT018, LAPS-IL036, LAPS-MA036, LAPS-MN026, LAPS-MO011, LAPS-NY016, LAPS-OH007, OR013, SCOR   
Study
Alliance-A151939
Multiple Studies, or Legacy Studies in Alliance Study:
CALGB-80702
Phases:
N/A, 3
Keywords: